Media coverage about Novavax (NASDAQ:NVAX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novavax earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.8347363210104 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the media headlines that may have impacted Accern’s rankings:

Several analysts have weighed in on NVAX shares. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 target price on shares of Novavax in a report on Friday, July 21st. BidaskClub lowered Novavax from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Chardan Capital reissued a “neutral” rating and issued a $1.50 target price on shares of Novavax in a report on Thursday, July 27th. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. Finally, Ladenburg Thalmann Financial Services raised Novavax from a “neutral” rating to a “buy” rating and set a $1.60 target price on the stock in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. Novavax presently has an average rating of “Hold” and an average target price of $3.05.

Novavax (NASDAQ:NVAX) traded down 5.56% during mid-day trading on Wednesday, reaching $1.02. The company’s stock had a trading volume of 5,317,680 shares. The firm has a 50 day moving average price of $1.14 and a 200-day moving average price of $1.06. The company’s market capitalization is $295.70 million. Novavax has a 1-year low of $0.73 and a 1-year high of $1.78.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The company had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.15 million. During the same period last year, the firm earned ($0.29) EPS. The firm’s revenue for the quarter was up 168.0% on a year-over-year basis. On average, equities analysts predict that Novavax will post ($0.62) EPS for the current fiscal year.

In other news, Director James F. Young sold 175,000 shares of Novavax stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total transaction of $185,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.00% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Insider Buying and Selling by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.